April 14, 2019 EASL 2019 – Research reminds hep B bulls that progress will be slow Presentations from Assembly Biosciences and Spring Bank Pharmaceuticals could disappoint those hoping to see more definitive steps towards a functional cure for hepatitis B.
September 13, 2018 Looking for new mechanisms to cure hepatitis B A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.
